One of the heroes of the RAC story is Bisantrene. The drug hasn’t disappointed in the clinic and has been saving patient’s lives. There has been tremendous validation of the science in and outside the company. There has been the Triangle report which provides external perspective on the commercial value of the cardio protection capabilities if Bisantrene can prove this in humans. Ignore the price movements and read the announcements sequentially, you will learn about the company and the drug. That’s my suggestion. Good luck.
Industry news, page-1741
-
- There are more pages in this discussion • 114 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.62 |
Change
0.015(0.93%) |
Mkt cap ! $276.0M | |||
| Open | High | Low | Value | Volume |
| $1.69 | $1.69 | $1.55 | $456.4K | 284.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $1.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.62 | 2659 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |